0.60
+0.021(+3.62%)
Currency In USD
| Previous Close | 0.58 |
| Open | 0.6 |
| Day High | 0.64 |
| Day Low | 0.58 |
| 52-Week High | 17.83 |
| 52-Week Low | 0.46 |
| Volume | 355,727 |
| Average Volume | 864,714 |
| Market Cap | 32.08M |
| PE | -0.23 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 1.97 |
| Change | 0.02 |
If you invested $1000 in ALX Oncology Holdings Inc. (ALXO) since IPO date, it would be worth $20.03 as of April 25, 2025 at a share price of $0.601. Whereas If you bought $1000 worth of ALX Oncology Holdings Inc. (ALXO) shares 3 years ago, it would be worth $39.77 as of April 25, 2025 at a share price of $0.601.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
GlobeNewswire Inc.
Apr 07, 2025 12:00 PM GMT
ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platformALX2004, the company’s first ADC, was fully design
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
GlobeNewswire Inc.
Mar 05, 2025 1:00 PM GMT
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancersAdvancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage develo
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
GlobeNewswire Inc.
Feb 27, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and